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                                             ABSTRACT 
 
BACKGROUND: 
      Organophosphorus compound(OPC) poisoning is very common in 
india and it is a very important cause of morbidity and mortality in such 
patients. Many factors determine the outcome in OPC poisoning. But so 
far, there are no properly conducted case control studies to analyse 
individual parameters in OPC poisoning. Hypokalemia is common in this 
scenario, and case reports are available which quote its significance.  
AIM: 
      In this study of 50 patients, the impact of hypokalemia in OPC 
poisoning, has been studied.  
  EXCLUSION CRITERIA: 
     Diseases or drugs that can modify serum potassium levels have been 
excluded from the study.  
OBSERVATION AND RESULTS: 
    In this study hypokalemia was associated with increased mortality and 
prolonged duration of mechanical ventilation, both of which are 
statistically significant with p values of 0.039 and 0.037 respectively. 
 
 
CONCLUSION: 
    Hypokalemia can be used as a reliable and cost effective marker of 
worse outcomes in the setting of OPC poisoning. 
KEY WORDS:  
   OPC poisoning, Hypokalemia, mechanical ventilation, atropine, 
pralidoxime and respiratory failure. 
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INTRODUCTION 
Organophosphorus compounds (OPCs) are common pesticides used 
in agriculture in India. Inappropriate handling, easier availability, and lack of 
adequate knowledge contribute to increased incidence of poisoning with these 
compounds in India which are also responsible for associated worse outcomes. 
Poisoning holds fourth position in leading causes of death in India.            
According to statistics given by WHO, approximately a millioncases 
of accidental and about 2 million cases of suicidal attempts usinginsecticides 
occur worldwide annually. 
          Many factors influence outcome in OPC poisoning like 
severity of poisoning, development of respiratory failure, availability of 
mechanical ventilation and so on. 
         In the current study, i am trying to assess hypokalemia in OPC 
poisoning and its impact on the outcome. 
 
 
 
  
2 
 
 
AIMS AND OBJECTIVES 
 
1) To assess hypokalemia in the setting of OPC poisoning 
 
2) To correlate hypokalemia with various clinical parameters and outcome. 
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REVIEW OF LITERATURE 
Organophosphorus(OPCs)  insecticides are one of the most 
commonly used insecticides in India and Asia.(1) Annually it is responsible for 
almost 2,00,000 deaths.(2) In some instances, severe poisoning may occur as 
an occupational hazard. Organophosphorus insecticides possess anticholine 
esterase property. It is not a common health issue in developed nations because 
access to poisons are restricted. Tetraethylpyrophosphate (TEPP), was the first 
Organophosphorus insecticide to be developed. Organic phosphorus 
compounds (OPCs) and carbamates are routinely used in India. These 
insecticides possess anticholine esterase property.  
WHO classification of insecticides include five group 
Extremely hazardous  - Class Ia,  
Highly hazardous - Class Ib, 
Moderately hazardous - Class II, 
Slightly hazardous - Class III  , and  
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“Active ingredients unlikely to present acute hazard in normal use”. 
In our toxicology ward, following classification system is being used. 
 
HIGHLY TOXIC: 
Monochrotophos, 
Phosphomidan, 
Ethyl parathion, 
Chlorthophos, 
Demeton S Methyl, 
Carbophenothion, 
Methyl parathion, and Phroate. 
 
MODERATELY TOXIC: 
Fenthion, 
Formothion, 
Malathion, 
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Fenitrothion, 
Diazinon, 
Temephos, 
Chlorpyriphos, and Methyl primiphos. 
 
OTHERS: 
Ediphenophos, 
Phosphenidon, 
Triazophos, 
Azinphos, 
Dimethoate, 
Parathion, 
Prophenophos, 
Quinalphos, and 
Jodfenphos. 
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Poisoning can occur either accidentally or intentionally. Direct 
contact through skin can be lethal. Chemically OPCs are classified into four 
groups, 
Phosphorylcholines – group 1,  
Fluorophosphates – group 2,  
Cyanophosphates – group 3 and  
Multiple constituents – group 4. 
PHARMACOLOGY: 
A syndrome of cholinergic excess results from inhibition 
ofanticholineesterase enzyme leading to accumulation of ACh in concerned 
receptors. If anticholineesterase enzyme is inhibited before the poison is 
metabolised in the body they are known as directly acting OPCs(oxons). But 
majority of commonly used OPCs such as parathion and malathion are 
prodrugs only. These compounds bind at the active site of  anticholine esterase  
enzyme in the hydroxyl group. This chemical reaction inactivates the enzyme 
efficiently. This also results in development of a reversible but stable bond 
between the enzyme and the OPC. Because of reversibility of the bond, the 
active state of enzyme can be regenerated which is accelerated by the oximes 
such as obidoxime and pralidoxime. However if the oximes are not 
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administered early and sufficiently the bond between the enzyme and poison 
become irreversible by a phenomenon known as “ aging”.  
Once this happened the enzyme cannot be reactivated by the oximes. 
(3) After aging has occurred the De-novo synthesis of enzyme is required to 
replenish enzyme levels. 
 
PHARMACOKINETICS: 
OPCs are absorbed well following  
inhalation,  
ingestion or  
skin contact and  
through GIT,  
lungs,  
mucous membranes and conjunctiva.  
Presence of prior skin disease enhance absorption and toxicity.(4) 
poisoning can be divided into acute or chronic even though such a 
classification may not be relevant clinically. OPCs are highly lipid soluble so 
their volume of distribution is large. So they are accumulated in tissues and fat 
and protected from detoxification by metabolism. 
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Concentrations are highest in adipose tisssues. Recurrence of 
cholinergic crisis may occur following their redistribution into circulation.  
OPCs which are prodrugs, are activated by cytochrome P 450 
enzymes. CYP3A4, CYP2B6 and CYP1A2 are few examples of them. It occurs 
mainly in liver and intestinal mucosa.(5) 
 
PATHOPHYSIOLOGY: 
ACh is the neurotransmitter in  
autonomic ganglia both sympathetic and parasympathetic,  
neuromuscular junction of skeletal muscles,  
postganglionic parasympathetic nerve endings,  
secretomotor fibres to sweat glands, and  
synapses in CNS.  
During neurotransmission ACh is released into the synaptic cleft and 
binds to the receptors in postsynaptic membrane. These receptors are divided 
into muscarinic (present mainly glands of various organs, heart,GIT and CNS) 
and nicotinic( present in the autonomic ganglia and neuromuscular junctions). 
Muscarinic receptors are G protein coupled receptors and nicotinic receptors 
are ligand gated ion channels.  
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Stimulation of these receptors result in generation and propagation of 
action potentials or other post synaptic events.Normallyanticholine esterase 
deactivate ACh into acetate and choline.  
Following its release into synaptic cleft ACh is rapidly hydrolysed. 
Choline reuptake into the presynaptic terminal is mandatory for the 
regeneration of ACh. Apart from skeletal muscles and nervous tissue AChE is 
also found in RBCs the levels of which almost correlates with enzyme activity 
of nervous tissue in the acute setting.(6) 
Butyryl choline esterase (BuChE) is found in  
plasma,  
CNS , 
heart,  
pancreas and  
hepatic tissue.  
It is synthesised in the liver. Its activity can be assessed and has 
important clinical utility particularly in anaesthesia.  
Majority of clinical features of OPC poisoning is due to AChE 
inhibition, many other enzymes are also susceptible. Its signifigance is not 
known. (7) Usually commercially available insecticides contain coformulants 
other than OPCs. The ingestion of these substances also occur in settings of 
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poisoning, their effects are difficult to assess clinically. These coformulants 
contain surfactants and organic solvents.  
Following inhalation they can cause aspiration pneumonitis, the risk 
of which is substantially high following coma and respiratory distress that 
occurs in OPC poisoning. Its management is difficult. 
 
CLINICAL FEATURES: 
ACUTE SYMPTOMS: 
Clinical features are due to excessive activation of cholinergic in the 
above mentioned sites.  
Typical patient is with severe poisoning, one who is  
comatose,  
pinpoint pupils,  
paralysis of muscles,  
sweating,  
loose stools,  
excessive lacrimation,  
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oral secretion and  
odour of OPC.  
Findings will not be typical in less severe poisoning. The onset of 
clinical features depends upon severity, route and individual OPC.  
Clinical features can be summarised as follows: 
SYMPATHETIC MANIFESTATIONS: 
CNS: 
disorientation,  
delirium,  
hallucinations,  
unconsciousness, and  
seizures. 
OTHERS: 
pupillary dilatation,  
tachycardia,  
increased BP,  
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retention of urine and  
hyperglycemia 
PARA SYMPATHETIC MANIFESTATIONS: 
CNS: 
Confusion,  
delirium,  
coma and  
convulsions 
OTHERS: 
Papillary constriction,  
increased lacrimation,  
excessive salivation,  
bradycardia,  
bronchospasm,  
diarrhoea and,  
bladder incontinence 
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SKELETAL MUSCLES: 
Neuromuscular weakness,  
fasciculations and  
paralysis. 
Patients consuming large amounts of poison and directly acting OPCs 
will manifest within few minutes after consumption. Almost all the patient will 
show symptoms within 24 hours. Lipid solubility of OPCs also determine the 
toxicity. Compounds with high fat solubility are distributed fast into the fat 
stores. So their toxicity will be somewhat less.  
      But the symptom of toxicity will worsen as redistribution of the 
poison occurs. 
The occurrence of respiratory paralysis may be delayed with 
compounds with high lipid solubility like fenthion than compounds with low 
lipid solubility.(8) Other features of poisoning which includes persistent 
cholinergic signs can occur for a longer duration in compounds with high fat 
solubility as they are released into the circulation again.  
Patients may have variety of CNS manifestations. Since majority of 
patients are alert and conscious, they usually complaints of the following 
symptoms.  
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Anxiety,  
sleeplessness,  
cephalgia,  
giddiness,  
blurring of vision,  
depression,  
increased tremulousness, and  
other nonspecific complaints.  
The conscious level of the patient can deteriorate in a rapid manner 
from confusion, lethargy to coma. The patients may show inappropriate 
behaviour. Convulsions can occur probably due to cholinergic toxicity.  
Since both sympathetic and parasympathetic systems contain 
acetylcholine receptors the clinical features vary. Miosis is considered to be the 
most consistent sign. Increased bronchial secretion may mimic as pulmonary 
edema.(9) 
Muscarinic cholinergic features may not be dramatic clinically. 
Because of sympathetic stimulation patient may have leucocytosis.(9) The 
same is the cause for hyperglycemia that can occur along with ketosis. This can 
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mimic ketoacidosis. Hypoglycaemia has also been reported but its mechanism 
is not known.(10) 
Hyperglycemiamay be related to individual compound like malathion 
rather than whole of OPCs.(10)  
Increased amylase levels may occur in OPC poisoning. Pancreatic 
edema may occur alone or in combination with pancreatitis in OPCs.(11) 
This is common with malathion. Hepatic transaminases may also 
increase.(12)  
CVS manifestations are an admixture of sympathetic and 
parasympathetic effects. Pulse rate may be normal, bradycardia or tachycardia 
can also occur. This poisoning may be associated with QT prolongation and 
life threatening arrhythmia.(13)  
Hypotension can occur and can be troublesome in poisoning with 
high lipid soluble substance like dimethoate. If respiratory failure occur along 
with hypotension vasopressors may become mandatory. Such a scenario do not 
occur with other compounds.  
Respirory system is affected in many ways. It is usually due to an 
interplay of following factors.  
Increased bronchial secretions,  
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bronchoconstriction,  
paralysis of intercostals and diaphragm, and  
decreased central drive for respiration.  
This will result in hypoxemia and ultimately in respiratory arrest 
which accounts for death in most circumstances. The first two factors will 
respond to atropine adequately but the later two will not. Securing the airway 
with intubation and mechanical ventilation may be needed to manage the 
situation. Aspiration pneumonitis can occur and patient may land up in ARDS.  
ACh acts in neuromuscular junctions through nicotinic receptors. Its 
mechanism is similar to neuromuscular blockade by an depolarising agent 
which will lead to fasciculations and muscle weakness. This finding may not be 
seen even in severe poisonings sometimes.  
Cranial nerve palsies are not common. Rarely nicotinic features alone 
occur in the absence of cholinergic features.  
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DELAYED COMPLICATIONS: 
INTERMEDIATE SYNDROME: 
Cardinal features of this syndrome are, 
Delayed onset of muscle weakness, 
Occurring after 24 to 96 hours of acute intoxication, 
Resolution of cholinergic symptoms. 
Clinically patients may have, 
Weakness of proximal muscles particularly flexors of neck, 
Cranial nerve involvement and  
Respiratory muscle paralysis. 
Patients are usually conscious unless they have pneumonia or 
hypoxic ischemic encephalopathy. As fatal respiratory arrest may occur early 
recognition of symptoms are crucial. Usually neck muscle weakness ie., 
difficulty in raising the head from the bed is the first sign. 
The pathophysiology of this syndrome is largely unknown. Because 
of neuromuscular dysfunction, weakness of intercostals muscles and diaphragm 
will lead to respiratory failure. As consciousness is preserved in uncomplicated 
cases, lack of central respiratory drive is not a likely mechanism.  
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It is suggested that overstimulation of neuromuscular junction will 
ultimately result in down regulation of synaptic mechanisms(14). As repair of 
these processes may take long time, weakness may persist longer. 
The incidence have predilection towards certain compounds like 
fenthion, parathion and malathion. Former has the highest reported 
incidence(15). Clinical recognition is the most reliable way to identify this 
syndrome(16). 
 Electromyogram in these patients will show “tetanic fade” 
suggestive of involvement of pre as well as post synaptic components.  
Some studies suggest that intermediate syndrome may be attributed 
to “insufficient oxime therapy”(17). The management of this syndrome is 
mainly supportive in the form of mechanical ventilation and airway protection. 
Atropine or pralidoxime do not have substantial role in this syndrome except 
that they will be useful in treating cholinergic symptoms. Usually, resolution of 
paralysis and weakness may take several days from 5 to 18 days. 
DELAYED NEUROPATHY: 
Chronic exposures to OPCs may result in peripheral neuropathy. This 
may also occur several days after acute intoxication. “Organic phosphorus–
induced delayed neuropathy (OPIDN)” occurs from the inhibition of the 
enzyme “neuropathy target esterase”.  
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This enzyme plays a major role in maintaining the phospholipid 
components of cell membrane and involved in cellular transport. Usually large 
fibres are affected which may reveal axonal degeneration pathologically.  
Carbamates usually do not cause neuropathy except carbofuran which 
has been implicated in some cases. Some association between OPCs and 
parkinsonism has also been suggested. 
BEHAVIORAL TOXICITY: 
Acute as well as chronic exposure to OPCs can cause behavioural 
changes. Symptoms being,  
confusion,  
depression,  
anxiety,  
fatiguability,  
irritability,  
drowsiness and  
psychosis.  
Basal ganglia involvement has also been described. 
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DIAGNOSIS: 
Diagnosis may be straight forward if the patients present with 
cholinergic crisis. As history may not be reliable in considerable number of 
cases, other diagnostic tests may be needed.  
Treatment in acute poisoning should never be delayed till the 
confirmation of diagnosis.  
The most appropriate tests are, 
1)Measurement of specific OPCs and their metabolites in tissues 
2)Cholinesterase activity in blood or plasma. 
Unfortunately such assays may not be available within few hours 
of poisoning. Moreover standardised data describing “normal range” as well 
as “toxic concentrations” are not well established. 
CHOLINESTERASE ACTIVITY: 
The commonly measured cholinesterases are “butyryl 
cholinesterase (BuChE, plasma cholinesterase)” and red cell cholinesterase. 
BuChE is produced in liver. It is secreted into blood to metabolise 
xenobiotics. The latter is found in RBCs. Inhibition of these enzymes can 
serve as the marker of poisoning. But enzyme level in RBCs will predict 
AChE activity in neurons in acute poisoning(18). 
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After poisoning BuChE will be the first one to fall and followed 
by RBC enzyme. When patient is presenting with symptoms activity of both 
the enzymes will be significantly lower than baseline levels. 
Levels of these enzymes at the time of admission may not 
correlate with the outcome.  
RED CELL CHOLINESTERASE: 
As stated previously enzyme activity in the RBCs may correlate 
with AChE levels in the neural tissue. When the RBC enzyme level is less 
than 30%, neuromuscular junction dysfunction occurs.(19) Its level can be 
correlated to hematocrit values. 
If oximes are not used, the enzyme activity in the RBCs will reach 
normal levels after many weeks only. Its activity will also be reduced,in 
patients with, 
perniciousanemia,  
antidepressants, and  
antimalarials. 
For assessing enzyme activity, blood should be collected in 
appropriate collecting tubes, if they contain fluoride, it will inactivate the 
enzymes permanently resulting in false low values.  
22 
 
It must contain anticoagulant, EDTA to assess RBC enzyme 
activity not for BuChE. 
ATROPINE CHALLENGE: 
This can be used when history is not available or reliable in the 
setting of suspected OPC poisoning. Atropine in a dose of 1 mg in adults 
and 0.05 mg/kg in children will produce antimuscarinic symptoms like 
mydriasis, tachycardia, and or dry mucous membranes in an unexposed 
individual. If cholinergic symptoms persist even after atropine injection, it 
strongly suggests OPC poisoning. 
ELECTROMYOGRAM: 
“Spontaneous repetitive potentials or fasciculations followingsingle 
nerve stimulation resulting from persistent acetylcholine at nerve terminals”  
can be used as a reliable indicator of early OPC poisoning. 
DIFFERENTIAL DIAGNOSIS: 
          This may include following 
1)Anticholinesterase medicines like  
neostigmine,  
physostigmine,  
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pyridostigmineand  
echothiophate iodide. 
2)Cholinomimetics like  
Pilocarpine,  
Carbachol,  
Aceclidine,  
Bethanechol,  
Methacholine 
3)Nicotine Alkaloids like  
Coniine,  
Lobeline, and  
Nicotine 
4)Carbamate insecticides 
5)muscarine-containing mushrooms 
MANAGEMENT 
Important components of managing OPC poisoning are, 
1)protection of airway and if needed mechanical ventilation 
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2)stabilisation of cardiorespiratory systems 
3)control of seizures 
Protection of airway can be ensured by endotracheal 
intubation early and mechanical ventilation particularly positivepressure 
ventilation in unconscious patients, in significantly weak muscle power, 
and in patients who cannot handle increased secretions.  
ANTIMUSCARINIC THERAPY: 
Simultaneous management of cholinergic crisis is an integral 
part of patient care since it will reduce respiratory secretions and 
improve oxygenation.  
 
Atropine is a competitive muscarinic receptor antagonist 
which counteracts, 
increased secretions,  
pupillary constriction,  
bronchospasm,  
loose stools,  
vomiting,  
sweating and  
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bladder continence.  
Intravenous atropine in the dose of 1 to 3mg according to the severity 
of poisoning in adults and in children at a dose of 0.05mg/kg upto adult dose 
depending upon the response. 
Atropinisation: 
Patient is said to have atropinised if he has following features.  
Dry mucous membranes,  
absent or decreased bowel sounds,  
increased pulse rate,  
decreased oral and respiratory secretions,  
no bronchospasm and  
pupillary dilatation.  
Since major cause of mortality is cardiorespiratory failure, its 
function should guide the management rather than pupil size or wet skin. 
Target of atropine therapy is to have a BP of 90 mm of Hg systole, a 
pulse rate of atleast 80/mt and a clear lungs. 
Once atropinisation is achieved patients can be maintained 
with atropine infusion upto 2mg/hr and in children at a dose of 
0.025mg/kg/hr.  
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Complete absence of bowel sounds,  
severe tachycardia,  
mydriasis and  
bladder retention  
allcan be the signs of “overatropinisation” which can be 
detrimental because of hyperthermia and atropine induced  delirium. 
However tachycardia may have multiple causes like  
dehydration,  
aspiration pneumonitis and  
delirium. 
High doses of atropine may be needed to counteract  
bronchospasm,  
increased secretions and  
bradycardia. 
Some heavily poisoned individuals required even upto 1 gram of 
atropine in 24 hrs.  
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Atropine cannot reverse the nicotinic side effects of OPC 
poisoning. So patients should be monitored for skeletal muscle 
weakness of proximal group particularly neck muscle weakness.  
Once identified, patients should be observed for respiratory distress 
and promptly intubated. Mechanical ventilation should be initiated according to 
the need. 
 If patients develop CNS toxicity due to atropine and there are signs 
of peripheral cholinergic signs like  
bronchorrhoea,  
vomiting or  
bradycardia 
glycopyrrolate can be substituted for atropine.  
This is equally efficacious and safe.(20) Like atropine, large doses of 
glycopyrrolate may be required in severe intoxication. 
OXIMES: 
OPCs phosphorylate the AChE enzyme, active form of enzyme can 
be regenerated by hydrolysis. This slow process can be accelerated to many 
folds by administration of oximes like obidoxime or pralidoxime chloride.(21) 
This will mitigate the nicotinic as well as muscarinic features.  
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Oximes can be useful even if they are administered late in the 
course of poisoning particularly in fat soluble OPCs. As a rule they 
should be given as early as possible.  
Side effects include  
vomiting,  
diastolic hypertension,  
neuromuscular blockadeand  
visual disturbances.  
DIAZEPAM: 
Diazepam administered with oximes decrease incidence of 
seizures and improve survival and neuropathy(22). It can also reduce 
brain damage from OPC related seizures.  
Phenytoin is ineffective in toxin induced seizures. Diazepam is not 
recommended in all cases of OPC poisoning. 
DECONTAMINATION: 
All the clothing should be removed in order to decrease cutaneous 
absorption. Medical personnel should wear double gloves and protective apron. 
Skin must be triple washed with water and soap. Skin soiled with contaminated 
vomitus and stools can absorb the poison and should be washed 
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thoroughly.Stomach wash should be given in all patients unless 
contraindicated. 
POTASSIUM: 
Potassium is an important intracellular ion required for many vital 
cellular functions. If its serum concentrations are altered, serious clinical 
manifestations can occur. 70 to 150 mmol of potassium is present in a typical 
western diet daily. Its levels are maintained between 3.5 to 5 mM. 
DISTRIBUTION: 
        After being absorbed from GIT, potassium is dietributed mainly 
into intracellular compartment where it is the major cation and also into ECF. 
Its concentration is about 100 to 120 mmol/l in the cytoplasm.  
Total potassium content in ithe ICF compartment in a healthy adult is 
about 3000 to 3500 mmol. Majority (70%) of which is present in muscles and 
the remaining in bone, skin, RBCs and liver.  
Only upto 2% of potassium is present in ECF. It is produced by the 
action of Na+,K+-ATPase pump which is present in almost all the cells. This 
pump transports three sodium ions extracellularly in exchange for 2 potassium 
ions intracellularly.  
Membrane potential is mainly determined by this differential 
distribution of these cations which leads to development of a more 
electronegative intracellular compartment.  
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This electric potential is mandatory in neural function and contraction 
of muscles.  
Serum levels of this cation is tightly regulated by various 
mechanisms. A “feed forward” system is said to exist in GIT or portal sensors 
for potassium which helps in renal excretion of potassium by the mechanisms 
independent of serum aldosterone or potassium levels(23).  
This reflex mechanism aids the kidney to balance between daily 
intake and daily excretion of potassium through kidneys.  
Factors maintaining the distribution of potassium can be divided into 
those decreasing its levels and  
those increasing its levels. 
     Serum levels are decreased by,  
insulin,  
beta agonists,  
alkalosis and  
alpha blockers. 
Serum levels are increased by  
acidosis,  
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hyperglycemia,  
beta blockers,  
alpha agonists,  
hyperosmolality and  
exercise. 
Acidosis caused by inorganic anions like NH4Cl or HCl will produce 
hyperkalemia by unknown mechanisms. But organic anions usually do not 
produce such an effect. Beta2 agonists and insulin activate Na+,K+-ATPase 
and thereby shifts potassium intracellularly.  
Activation of Beta2 receptor will increase the intracellular 
cAMPwhich in turn stimulate Na+,K+-ATPase pump. Alpha receptor 
activation has the opposite effect. 
ALDOSTERONE: 
        By 2 major mechanisms this hormone reduces serum potassium.  
1) It causes redistribution of potassium intracellularly.  
2) It enhances renal excretion of potassium & to a minor 
extent in GIT. 
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HYPEROSMOLALITY: 
Hyperosmolality drives water out of the cells, intracellular potassium 
conaentration rises. This inhibits Na+,K+-ATPase pump and intracellular 
levels are normalised. This can occur only with “effective osmoles” as it occurs 
in hyperglycemia in diabetic patients or with administration of mannitol. If 
hyperglycemia occurs in non diabetics in whom endogenous insulin is normal, 
it will enhance insulin secretion leading to hypokalemia. 
EXERCISE: 
Exercise will cause alpha receptor activation resulting in 
hyperkalemia which will cause dilatation of arteries leading to increased blood 
flow to skeletal muscles. Simultaneous beta receptor activation will reduce its 
severity but same can lead to hypokalemia following exercise.  
If severe hypokalemia occurs in susceptible individuals it can lead to 
rhabdomyolysis. 
RENAL HANDLING OF POTASSIUM: 
Potassium homeostasis on long term basis is effected through 
kidneys. This occurs almost exclusively in the collecting duct. Since potassium 
is not protein bound, it is freely filtered across the glomerulus.  
About 60 to 70% is reabsorbed in the proximal convoluted tubule. A  
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modest net reabsorption occurs in “loop of henle”. This can be altered 
by a loop diuretic. 
Potassium excretion is principally regulated in distal collecting duct 
and tubules active secretion combined with reabsorption. Cortical collecting 
duct possess the principal collecting duct which contains “apical sodium 
channel (ENaC)”. This channel reabsorbs sodium which activates Na+,K+-
ATPase in the basolateral membrane. So intracellular potassium levels rise. 
This potassium is secreted into luminal fluid by KClcotransporters 
and apical potassium channels. Potassium reabsorption occurs by the “apical 
H+,K+-ATPase” in the intercalated cells. This secretes H+ ions back to the 
luminal fluid. These 2 different processes ensure effective control of potassium 
through kidneys. 
Potassium secretion by the principal cells are tegulated by,  
flow rate of luminal fluid,  
sodium delivery to the distal tubules,  
serum aldosterone,  
potassium in ECF, and  
pH of ECF 
in the decreasing order of significance. 
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If “luminal flow rate” increases, it will reduce intraluminal potassium 
levels. This will increase concentration gradient for potassium across “apical 
membrane”. This will result in potassium secretion.  
Secondly it directly stimulates potassium secretion by altering apical 
membrane potassium gradient. 
DIURETICS: 
So if flow rate decreases hyperkalemia occurs. If reabsorption of 
sodium decreases, forces driving potassium secretion also decreases and 
hyperkalemia occurs. This how “Potassium-sparing diuretics,” act. They 
decrease sodium reabsorption either directly or indirectly.  
Thiazide and loop diuretics increase sodium delivery to the distal 
collecting ducts and enhance sodium absorption and hyperkalemiamay occur. 
ALDOSTERONE: 
        Aldosterone has many effects on potassium secretion by 
principal cells. It increases expression of Na+,K+-ATPase and “apical sodium 
channel (ENaC)”. This will lead to increased potassium secretion. 
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ACIDOSIS:  
Metabolic acidosis directly affect potassium channels and interstitial 
ammonia concentration thereby decreases potassium secretion. Respiratory 
acidosis has minimum influence on potassium secretion. 
Activity of “apical H+,K+-ATPase” is altered by  
potassium levels,  
pH, and  
aldosterone. 
Hypokalemia increases expression of H+,K+-ATPase leading to 
increased potassium absorption and reduced secretion. Aldosterone also 
increases expression of H+,K+-ATPase, and alleviate potassium secretion. 
Metabolic acidosis also affect H+,K+-ATPase activity and contribute to the 
development of hyperkalemia. 
CHRONIC KIDNEY DISEASE (CKD) AND POTASSIUM HANDLING: 
Potassium balance can be maintained to near normal levels until GFR 
falls substantially. This is because compensatory increase in potassium 
excretion by individual nephron. But CKD patients cannot handle an acute load 
of potassium effectively because of decreased functioning nephrons and 
limitations of compensatory mechanisms.  
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Drugs causing hyperkalemia like ARBs, ACEIs, and beta blockers 
have profound effect in CKD patients. 
HYPERKALEMIA: 
               It is defined as serum potassium level of 5.5 meq/dl. When 
it is more than 6Mm, it can be fatal.  
CAUSES: 
“Pseudo hyperkalemia” as occurs in  
- Hemolysis in vitro,  
- RBC membrane transport defects 
Extra cellular potassium shift as occurs in 
- Acidosis 
- Hyperosmolality due to mannitol or radiocntrasts 
- Beta blockers 
- Digoxin 
- “hyperkalemic periodic paralysis” 
- Rapid lysis of tumor cells 
- Amino acids like arginine and lysine 
Decreased excretion of potassium as occurs due to drugs like, 
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Aliskiren a renin inhibitor, 
ACE inhibitors, 
Succinyl choline, 
Aldosterone antagonists 
Angiotensin receptor blockers, 
“potassium sparing diuretics” 
Trimethoprim, 
Nafamostat, and 
Pentamidine, 
Decreasd delivery of potassium to tubules as occurs in 
Hypovolemia 
Heart failure 
Disuse atrophy 
Chronic kidney disease 
Acute oliguric renal failure 
 
 
38 
 
HYPOKALEMIA: 
Hypokalemia is defined as serum levels less than 3.6 mM.If renal 
functions are normal and patients are not on medications, less than 1% of 
population will develop either hypokalemia or hyperkalemia.  
So in the absence of drugs, occurance of either condition in a healthy 
adult should lead to suspicion of an underlying disease. But hypokalemia 
usually occurs with drugs or specific diseases such as patients on diuretics.  
CLINICAL MANIFESTATIONS: 
Hypokalemia can affect  
nerves,  
blood vessels and heart,  
gut,  
muscles and kidney. Elderly individuals do not tolerate hypokalemia  
unlike their younger counterparts. 
CARDIOVASCULAR SYSTEM: 
       Low potassium diet is associated with an increased prevalence of 
systemic hypertension. Potassium supplementation will reduce BP. 
Hypokalemia may cause sodium retention and lead to hypertension.  
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Fatal arrythmias like ventricular fibrillation can occur in 
hypokalemia. Risk of sudden cardiac death is high.  
HORMONAL: 
Hypokalemia will reduce insulin secretion and precipitate insulin 
resistance leads worsening of glycemic status and diabetic control(24).  
Thiazide induced hyperuricemia and hypokalemia may cause 
endothelial dysfunction and contribute to insulin resistance observed in patients 
on thiazide diuretics. 
SKELETAL MUSCLES: 
Because hypokalemia causes hyperpolarisation of cells of skeletal 
muscles, muscle contraction will be impaired. Hypokalemia reduces blood flow 
to skeletal muscles. Severe hypokalemia may cause rhabdomyolysis following 
exercise. 
KIDNEYS:  
Effects comprise of  
reduced blood flow to medullary region,  
increased resistance in renal vasculature,  
cystic and tubulo interstitial changes,  
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pH alteration, and  
retarded concentrating mechanisms of kidneys. 
CYSTIC AND TUBULO INTERSTITIAL CHANGES: 
Hypokalemia causes interstitial fibrosis particularly outer medulla. 
Even it is reversible, sometimes it may cause ranal failure. Hypokalemia can 
cause hypertrophy of renal parenchyma and may predispose to the development 
of renal cysts. 
ACID-BASE DISTURBANCE: 
Hypokalemia will cause metabolic alkalosis due to increased 
secretion of H+ ions. This may lead to a viscous cycle. If respiratory failure 
occurs because of hypokalemia it can result in respiratory acidosis. 
CONCENTRATION DEFECTS: 
Hypokalemia impairs concentrating mechanisms of kidneys leading 
to mild polyurea about 2-3 L/day.  
HEPATIC ENCEPHALOPATHY: 
Hypokalemia increases ammonia production in the kidneys. Nearly 
50% of this can enter systemic circulation and hepatic encephalopathy may 
worsen. 
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ETIOLOGY: 
Etiology of hypokalemia can be divided into 4 classes. 
1) Nonrenal potassium losses 
2) potassium losses through kidneys 
3) redistribution 
4) Pseudohypokalemia 
PSEUDOHYPOKALEMIA: 
This condition is due to an artefact not true hypokalemia like that 
occurs after phlebotomy. AML is the most common condition associated with 
this. Large numbers of tumour cells take up K+ intracellularly if blood is stored 
at room temperature for long time.  
REDISTRIBUTION: 
As previously mentioned hormones will influence the shift of 
potassium between ECF and ICF. 
NONRENAL LOSSES OF POTASSIUM: 
GIT and skin usually excrete small amounts of K+ daily. 
Occasionally, chronic diarrhoea or excessive sweating causes significant 
potassium loss(25).  
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RENAL LOSSES: 
the most common etiology. 
Medicines: 
Both loop diuretics and thiazide increase urinary K+excretion and 
adjusted for their dieresis, thiazides commonly causes hypokalemia. Penicillin 
analogues, like carbenicillin, increases urinary K+ excretion. 
AmphotericinB increases collecting duct K+ secretion directly. 
Cisplatinmay induce hypokalemia.  
Hormones: 
As stated previously aldosterone causes renal loss of K+. 
Deficiency of Magnesium:      
Magnesium depletion can cause severe hypokalemia particularly in 
the setting of diuretic therapy. This should be suspected if K+ replacement does 
not correct the K+ loss. 
Intrinsic Renal Mechanisms: 
   These conditions are rare. Bartter syndrome will have  
normal or low BP,  
metabolic alkalosis,  
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hypercalciuria and  
hyperreninemia.  
Gitelman’ssyndrome will have same features except 
hypercalciuriainstead it will have hypocalciuria.  
Liddle syndrome will have  
hypokalemia,  
severe systemic hypertension,  
hyporeninemia and  
decreasedaldosterone levels. 
Bicarbonaturia: 
Bicarbonaturia may occur because of  
distal RTA( renaltubular acidosis),  
metabolic alkalosis,  or  
in the  treatment of proximal RTA(renal tubular acidosis). 
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“HYPOKALEMIC PERIODIC PARALYSIS (HYPOKPP)” 
Onset  of “HypoKPP” occurs during adolescence. This disease is 
more common in men than women. If “episodic weakness” occurs after the age 
of 25 years HypoKPP can almost be ruled out.  
High carbohydrate or sodium diet will provoke attacks of weakness 
which proximal rather than the distal muscles of limbs. Involvement of cranial 
nerves is not common. It may be fatal if respiratory muscles are involved 
though these are usually not affected.  
Cardiac arrhythmias may be deadly if hypokalemia is severe. 
“Thyrotoxic periodic paralysis” will mimic HypoKPP. But this condition will 
improve after the treatment with anti thyroid drugs. Hypokalemia during the 
attacks of weakness in the abscence of other causes will establish the diagnosis. 
EMG may show reduction in amplitude, and in severely weak muscles even 
electrical silence. 
TREATMENT: 
Oral potassium chloride in the dose of 0.2 to 0.4 mmol/kg can be 
given in the interval of 30 minutes. Intra venous treatment is needed only rarely 
in which case mannitol is preferred. Diets rich in carbohydrate and sodium 
should be avoided. Acetazolamide in a dose of 125 to 1000 mg, 25 to 100 mg 
of triamterene, or 25 to 100 mg of spironolactone may used as a prophylaxis. 
 
45 
 
DIAGNOSIS: 
redistribution or pseudohypokalemia should be excluded first. The 
above said four categories should be looked for. If diuretic therapy or 
metabolic alkalosis is the cause, they will cause urinary loss of K+. 
Hypomagnesemia as a result of diuretic therapy, will cause hypokalemia which 
is refractory to treatment. 
Diagnostic workup can be explained as follows. 
Step1. Is there an abnormal leucocytes present? 
If yes, pseudohypokalemia may be suspected and it should be 
confirmed by rapid separation of plasma or storing blood at 4 degree C. 
If leucocytes are normal, move to the next step. 
Step 2. Is there evidence for recent insulin, elevated aldosterone, 
adrenergic drugs, or theophylline? 
If yes, hypokalemia is due to redistribution. 
If there is no such evidence, move to further workup. 
Step 3. Is there any fluid loss from skin or GIT? 
If yes, hypokalemia is due to non renal loss. If it is not, 
Step 4. Assess urinary potassium levels. 
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If 24 hours urinary excertion is less than 20 mmol/day then 
hypokalemia may be due to poor oral intake, recent diuretic use or recent GI 
loss. 
Step 5. If potassium excretion is more than 20 mmol/day, two 
scenarios can be suspected 
Scenario 1.hypokalemia may be due to  
Drugs like diuretics, amphotericin or aminoglycosides. 
Or it is due to bicorbanaturia orHypomagnesemia. 
Scenario 2. Assess BP 
If it is low,Bartter or Gitelman syndrome should be considered. 
If BP is high, assess plasmaaldosterone and cortisol. 
If aldosterone is low with normal cortisol, liddle syndrome is the 
possibility. 
If aldosterone is normal or low with increased cortisol, 
cushing’ssyndrome should be suspected. 
If aldosterone is high with normal cortisol, hyperaldosteronism 
should beconsidered. 
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TREATMENT: 
 The risks of treatment should be balanced against the risk of 
hypokalemia. Treatment induced hyperkalemia may cause fatal “ventricular 
tachycardia or fibrillation”.  
The absolute indications are, 
1)“hypokalemic periodic paralysis (hypoKPP)” 
2)Patients with severe hypokalemia needing urgent surgery 
3)Ventricularectopics in the setting of acute coronary syndrome. 
       In such scenarios, intra venous KCl in a dose of 5-10mmol over 
15-20 minutes can be given an may be repeated as needed. ECG must be 
closely monitored. 
Whenever possible, KCl for chronic hypokalemia must be given 
orally. For IV therapy, 10 mmol/hour will be a safe dose. Dextrose containing 
solutions will aggrevate hypokalemia because it stimulates secretion of insulin.  
Treatment of underlying disease is essential. In cases of refractory 
hypokalemia, hypomagnesemia should suspected and treated if present. 
HYPOKALEMIA IN THE SETTING OF OPC POISONING: 
Hypokalemia is a common finding in OPC poisoning(26). Exact 
mechanisms by which hypokalemia occurs is not known. Proposed 
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mechanisms include, excessive vomiting, ganglionic stimulation related 
sympathetic overactivity, andhypomagnesemia. None of these mechanisms are 
proved. So far no randomised control trial has been conducted to assess 
hypokalemia in this setting. Only a few case reports are available. 
          When hypokalemia complicates this poisoning, it may interfere 
with neuromuscular synaptic functions which are already compromised 
because poisoning. It can induce cardiac rhythm abnormality which can 
adversely affect the outcome.(27) 
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MATERIAL AND METHODS 
SETTING: 
This study was conducted at the Institute of Internal Medicine, Rajiv 
Gandhi Government General Hospital and Madras Medical College. 
 
ETHICS COMMITTEE APPROVAL: 
Obtained. 
STUDY DURATION: 
This study was conducted over a period of six months. 
STUDY POPULATION: 
Patients admitted with history of organophosphorus compound 
poisoning in toxicology ward, Institute of Internal medicine. 
SAMPLE SIZE: 
Fifty cases admitted with history of organophosphorus compound 
poisoning. 
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TYPE OF STUDY: 
       Cross sectional study                      
INCLUSION CRITERION: 
Patients admitted with history of organophosphorus compound 
poisoning. 
EXCLUSION CRITERIA: 
Known kidney disease patients,  
heart disease patients,  
patients on diuretics. 
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DATA COLLECTION AND METHODS 
 
• Informed consent was obtained from each patient or the relative. 
• Patients had their history taken according to a Questionnaire and were 
subjected to clinical examination. 
• Renal function tests were done in all patients. 
• All the data were entered in the proforma(enclosed). 
• SPSS package and ANOVA was used to analyse the data. 
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 OBSERVATION AND RESULTS  
AGE AND HYPOKALEMIA 
 
 
Serum potassium 
levels meq/dl N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Age in years Hypokalemia 24 38.38 14.111 2.880 
Normal 26 34.12 13.364 2.621 
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INDEPENDENT SAMPLES TEST 
  
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 
 
    P 
VALUE 
  F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
         Lower Upper  
 
.278 
Age in years Equal variances 
assumed 
2.048 .159 1.096 48 .278 4.26 3.886 -3.553 12.072 
 Equal variances 
not assumed 
  1.094 47.129 .280 4.26 3.894 -3.574 12.093 
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SEX AND SERUM POTASSIUM LEVELS 
Serum potassium levels meq/dl 
Total 
 
Hypokalemia 
Normal  
 
Sex 
     Male Count 20 19 39 
 
% within Sex 
51.3% 48.7% 100.0% 
 
% within Serum potassium levels meq/dl 
83.3% 73.1% 78.0% 
 
Female 
Count 4 7 11 
 
% within Sex 
36.4% 63.6% 100.0% 
 
% within Serum 
potassium levels 
meq/dl 
16.7% 26.9% 22.0% 
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Total Count 24 26 50 
 
% within Sex 
48.0% 52.0% 100.0% 
 
% within Serum potassium levels meq/dl 
100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
SEX AND SERUM POTASSIUM LEVELS 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
 
P 
value 
Pearson Chi-
Square 
.765(b) 1 .382 
  
Continuity 
Correction(a) 
.284 1 .594 
  
Likelihood Ratio .774 1 .379 
  
 
.382 Fisher's Exact 
Test    
.501 .298 
Linear-by-Linear 
Association 
.750 1 .387 
  
N of Valid Cases 50 
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SEX AND SERUM POTASSIUM LEVELS 
 
 
 
 
 
 
 
Sex
FemaleMale
Count 
30
20
10
0
Serum potassium levels 
Hypokalemia
Normal
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SERUM POTASSIUM LEVELS (MEQ/DL) AND OUTCOME 
 
Serum potassium levels 
meq/dl 
Total 
 
Hypokalemia 
Normal  
 
Outcome 
     Death Count 10 4 14 
 
% within 
Outcome 
71.4% 28.6% 100.0% 
 
% within 
Serum 
potassium 
levels 
meq/dl 
41.7% 15.4% 28.0% 
 
Discharge 
Count 14 22 36 
 
% within 
Outcome 
38.9% 61.1% 100.0% 
 
% within 
Serum 
potassium 
levels 
meq/dl 
58.3% 84.6% 72.0% 
 
Total  Count 24 26 50 
 48.0% 52.0% 100.0% 
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% within 
Outcome 
 
% within 
Serum 
potassium 
levels 
meq/dl 
100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
 
P 
value 
Pearson Chi-
Square 
4.276(b) 1 .039 
  
Continuity 
Correction(a) 
3.072 1 .080 
  
Likelihood Ratio 4.369 1 .037 
  
 
.039 
 
Fisher's Exact 
Test    
.059 .039 
Linear-by-Linear 
Association 
4.191 1 .041 
  
N of Valid Cases 50 
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SERUM POTASSIUM LEVELS (MEQ/DL) AND OUTCOME 
 
 
 
 
  
Outcome
DischargeDeath
Count
30
20
10
0
Serum potassium levels
Hypokalemia
Normal
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INDIVIDUAL POISON AND POTASSIUM LEVELS 
 
 
 
 
 
 
 
Name of poison
TRIAZOPHOS
TEMEPHOS
PROPHENOPHOS
PHOSPHOMIDON
PARATHION
MONOCHROTOPHOS
METHYL
 PARATHION
MALATHION
FENTHION
DIMETHOATE
DIAZINON
CHLORTHIOPHOS
CHLORPYRIPHOS
ANILPHOS
ACEPHATE
Co
u
n
t
10
8
6
4
2
0
Serum potassium leve
Hypokalemia
Normal
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CHI-SQUARE TESTS 
 
Value df 
Asymp. 
Sig. (2-
sided) 
    P 
value 
Pearson Chi-
Square 
12.765(
a) 
14 .545 
 
.545 
Likelihood Ratio 17.393 14 .236 
N of Valid Cases 50 
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SERUM SODIUM LEVELS(meq/dl) AND SERUM POTASSIUM 
LEVELS(meq/dl) 
Serum potassium levels 
meq/dl 
Total 
 
Hypokalemia 
Normal  
 
Serum 
sodium level 
meq/dl 
     
< 135 Count 6 8 14 
 
% within 
Serum 
sodium level 
meq/dl 
42.9% 57.1% 100.0% 
 
% within 
Serum 
potassium 
levels 
meq/dl 
25.0% 30.8% 28.0% 
 
> 135 
Count 18 18 36 
 
% within 
50.0% 50.0% 100.0% 
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Serum 
sodium level 
meq/dl 
 
% within 
Serum 
potassium 
levels 
meq/dl 
75.0% 69.2% 72.0% 
 
Total Count 24 26 50 
 
% within 
Serum 
sodium level 
meq/dl 
48.0% 52.0% 100.0% 
 
% within 
Serum 
potassium 
levels 
meq/dl 
100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
P value 
Pearson Chi-
Square 
.206(b) 1 .650 
  
Continuity 
Correction(a) 
.019 1 .890 
  
 
.650 
Likelihood Ratio .207 1 .649 
  
Fisher's Exact 
Test    
.757 .446 
Linear-by-Linear 
Association 
.202 1 .653 
  
N of Valid Cases 50 
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SERUM SODIUM LEVELS(meq/dl) AND SERUM POTASSIUM 
LEVELS(meq/dl) 
 
 
 
 
  
Serum sodium level meq/dl 
> 135< 135
Count
20
18
16
14
12
10
8 
6 
4 
Serum potassium level
Hypokalemia
Normal
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SERUM POTASSIUM LEVELS AND DURATION OF HOSPITAL 
STAY(IN DAYS) 
 
Serum 
potassium levels 
meq/dl ean 
S
td. 
Deviation 
td. Error 
Mean 
Duratio
n of hospital stay 
in days 
Hypoka
lemia 4 .29 
3.
014 615 
 Normal 6 .08 
2.
992 587 
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INDEPENDENT SAMPLES TEST 
  
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
 
P 
value 
  F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
         Lower Upper 
 
 
 
 
Duration of 
hospital stay 
days 
 
Equal 
variances 
assumed 
.114 .738 .253 48 .802 .21 .850 -1.494 1.924 
 
 
.802 
 
Equal 
variances not 
assumed 
  .253 47.623 .802 .21 .850 -1.495 1.925 
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SERUM POTASSIUM LEVELS AND DURATION OF MECHANICAL 
VENTILATION ( IN DAYS) 
 Serum potassium levels meq/dl N Mean Std. Deviation Std. Error Mean 
Duration of 
mechanical 
ventilation days Hypokalemia 24 2.79 2.449 .500 
 Normal 26 1.42 2.062 .404 
 
  
71 
 
INDEPENDENT SAMPLES TEST 
  
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
 
 
P 
value 
  F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
         Lower Upper 
 
 
 
 
 
 
Duration of 
mechanical 
ventilation 
days 
Equal 
variances 
assumed 
.249 .620 2.143 48 .037 1.37 .639 .085 2.653 
 
 
 
.037 
 
 
 
 
Equal 
variances not 
assumed 
  2.128 45.163 .039 1.37 .643 .074 2.664 
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RESULTS 
AGE: 
            Of 50 patients studied, 24 patients had hypokalemia(serum potassium 
levels <3.6meq/dl) and 26 had normal serum potassium levels. The mean age 
for patients with hypokalemia was 38.38 and mean age for other was 34.12. 
This difference was statistically not significant( p value- 0.278) 
SEX: 
          In this study, totally 24 patients had hypokalemia. Of 39 male patients, 
20 patients (51.3%) had hypokalemia. Of 11 female patients, 4 patients(36.4%) 
had hypokalemia. This difference of 14.9% of increased incidence in male 
patients was not statistically significant.(p value0.382). 
MORTALITY: 
            During the study period, totally 14 deaths occurred. Among this 10 
patients had hypokalemia which accounts for 71.4% and the remaining 4 
patients had, normal serum potassium levels which accounts for, 28.6% and it 
is statistically significant(p value- 0.39). 
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INDIVIDUAL POISON AND POTASSIUM LEVELS: 
In this study, totally 15 different poisons were involved. Of 24 cases 
of hypokalemia, monochrotophos is responsible for maximum number of cases 
being involved in 8 cases followed by chlorpyriphos in 6 cases.Acephate, 
anilphos, diazinon, dimethoate, phosphomidon, and temephos did not cause 
hypokalemia in any cases. However this increased incidence with individual 
poisons are not statistically significant(p value- 0.545). 
 
SERUM SODIUM LEVELS AND SERUM POTASSIUM LEVELS: 
Of 50 patients totally, 14 had hyponatremia(<135 meq/dl) which 
constitutes 28%. Of this 6 patients had hypokalemia which accounts for  42.9% 
of hyponatremia. Of 24 patients with hypokalemia this 6 cases of hyponatremia 
accounts for 25%. This association is not significant statistically (p value- 
0.650). Hypernatremia did not occur in any patient. 
 
SERUM POTASSIUM LEVELS AND DURATION OF HOSPITAL 
STAY: 
In the current study mean duration of hospital stay in hypokalemia 
patients was 6.29 days, whereas in patients with normal potassium was 6.08 
days. Hypokalemia did not prolong hospital stay. ( p value- 0.802). 
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SERUM POTASSIUM LEVELS AND DURATION OF MECHANICAL  
VENTILATION: 
Out of 50 patients, 28 patients needed mechanical ventilation.  
All 14 patients who died had required mechanical ventilation. Of 28 
patients needed mechanical ventilation, 18 patients had hypokalemia.  
The mean duration of mechanical ventilation in hypokalemia patients 
was 2.79 days which is almost double as the mean duration in patients with 
normal potassium which was 1.42 days. This prolongation in mechanical 
ventilation was statistically significant ( p value- 0.037). 
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DISCUSSION 
NUMBER OF PATIENTS: 
Name of the study Number of patients: 
 
 
D.R.Mahadeshwara Prasad et al 50 
Lyzhnikov EA et al 73 
Current study 50 
 
In D.R.Mahadeshwara Prasad et al study, the author studied 
relationship between serum potassium levels with muscle twichings& 
fasciculations, respiratory distress, mortality and convulsions in 50 patients. 
In Lyzhnikov EA et al study, the relationship between plasma and 
RBC levels of potassium and sodium with mortality and ECG was analysed in 
73 patients with OPC poisoning. 
 
76 
 
AGE: 
Mean age of the patients in D.R.Mahadeshwara Prasad et al study 
was27.14 years. In current study mean age for patients with normal potassium 
was 34.12 years and for patients with hypokalemia was 38.38 years.. In 
Lyzhnikov EA et al Study age difference was not studied. 
 
GENDER: 
In D.R.Mahadeshwara Prasad et al study and Lyzhnikov EA et al 
Study the significance of gender and hypokalemia was not studied. In the 
current study, of 24 patients with hypokalemia, 20 were male patients and 4 
were female patients. 
 
MORTALITY: 
In Lyzhnikov EA et al Study, severe arrhythmia and cardiac arrest 
leadind to death occurred in 29 patients who are found to have hypernatremia 
and hypokalemia. In D.R.Mahadeshwara Prasad et al study, death occurred in 
patients with a mean potassium levels of 2.90 +/- 0.057 meq/dl(p value < 
0.001). In the current study, out of 14 deaths totally, 10 patients(71.4%) had 
hypokalemia . 
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INDIVIDUAL POISON AND POTASSIUM LEVELS: 
In Lyzhnikov EA et al Study, patients had poisoning with chlorophos, 
carbophos ,and thiophos. In D.R.Mahadeshwara Prasad et al study, significance 
to individual poison was not analysed. In the current study there is no 
statistically significant association between an individual poison and 
hypokalemia. 
 
SERUM POTASSIUM AND SERUM SODIUM LEVELS: 
In the current study, 14 patients had hyponatremia(<135 meq/dl).  
Of which, 6(41.6%) had hypokalemia but this was not significant 
statistically.( p value-0.650) None of the patients had hypernatremia. In 
D.R.Mahadeshwara Prasad et al study sodium disturbance was not studied. In 
Lyzhnikov EA et al Study, hypernatremia was associated with hypokalemia 
and icreased mortality. 
 
SERUM POTASSIUM LEVELS AND DURATION OF HOSPITAL 
STAY: 
In the current study mean duration of hospital stay in hypokalemia 
patients was 6.29 days, whereas in patients with normal potassium was 6.08 
days. Hypokalemia did not prolong hospital stay.( p value-0.802). 
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In both previously done studies, duration of hospital stay was not 
assessed.   
 
SERUM POTASSIUM LEVELS AND DURATION OF MECHANICAL  
VENTILATION: 
In D.R.Mahadeshwara Prasad et al study, both respiratory distress 
and mechanical ventilation taken together and statistically significant(p value < 
0.001). In the current study, mean duration of mechanical ventilation was 
prolonged(p value-0.037). In Lyzhnikov EAet alStudy, mechanical ventilation 
was not assessed. 
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LIMITATIONS OF THE STUDY 
 
• Because there is no randomisation, the influence of confounding factors 
like infection, and development of multi organ dysfunction cannot be 
eliminated. 
 
 
• As included in the criteria, patients with renal failure have been 
excluded. So electrolyte disturbance in this population cannot be 
assessed. 
 
• Number of female patients in the study group is small. 
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CONCLUSION 
• Hypokalemia increases both morbidity and mortality in 
organophosphorus compound poisoning significantly. 
 
• Hypokalemia can be used as a reliable and a cost effective marker of 
morbidity and mortality in organophosphorus compound poisoning. 
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PROFORMA 
 
NAME OF THE PATIENT  : 
AGE / SEX     : 
IP/OP NUMBER    : 
OCCUPATION    : 
ADDRESS     :  
CONTACT NUMBER   : 
COMPLAINTS    : 
PAST HISTORY    : 
TREATMENT HISTORY   : 
DRUG ALLERGY    : 
GENERAL EXAMINATION  : 
VITALS      : 
SYSTEMIC EXAMINATION  : 
CARDIOVASCULAR SYSTEM  : 
RESPIRATORY SYSTEM    : 
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ABDOMEN            : 
CENTRAL NERVOUS SYSTEM : 
SERUM POTASSIUM   :  
RENAL FUNCTION TESTS  : 
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PATIENT CONSENT FORM 
Study Detail :  HYPOKALEMIA IN ORGANOPHOSPHOROUS  
COMPOUND POISONING   
Study Centre : Institute of internal medicine,, Rajiv Gandhi 
Government  
General Hospital, Chennai. 
 
Patient’s Name 
 
: 
 
Patient’s Age :  
Identification  
Number 
:  
Patient may check (☑) these boxes 
 
  I confirm that I have understood the purpose of procedure for the above 
❏ 
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study.  
I have the opportunity to ask question and all my questions and doubts 
have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
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I hereby give permission to undergo complete clinical examination , 
biochemical, immunological test. ❏ 
 
 
Signature of Investigator      Signature/thumb impression 
 
 
Study Investigator’s Name:   Patient’s Name and Address: 
 
Dr.MARIRAJ.I.,
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MASTER CHART 
Serial 
no 
Sex Age Name of poison Serum 
potassium 
levels 
meq/dl 
Duration 
of 
hospital 
stay 
days 
Duration of 
mechanical 
ventilation 
days 
 
1 M 58 Prophenophos 2.6   10   5    138   Death 
2 M 50 Monochrotophos 3.1   6   3    136   Discharged 
3 M 55 Monochrotophos 2.8   4   4    139   Death 
4 F 28 Parathion 3   14   10    135   Discharged 
5 M 58 Chlorthiophos 4.1   6   3    138   Death 
6 M 27 Methyl parathion 2.8   6   3    138   Discharged 
7 M 24 Chlorpyriphos 4.2   5   1    137   Discharged 
8 M 21 Parathion 4.5   5   0    137   Discharged 
9 M 25 Parathion 3   5   0    135   Discharged 
10 F 25 Monochrotophos 2.4   10   5    136   Death 
11 M 23 Diazinon  4.8   5   0    134   Discharged 
12 M 23 Monochrotophos 4.5   5   0    137   Discharged 
13 M 45 Monochrotophos 3   7   4    140   Discharged 
14 M 21 Malathion 2.4   5   2    139   Discharged 
15 M 24 Chlorpyriphos 2.5   9   2    139   Discharged 
16 F 24 Monochrotophos 4.2   10   4    135   Discharged 
17 M 55 Monochrotophos 2.1   2   2    138   Death 
18 F 19 Methyl parathion 3   5   0    136   Discharged 
19 F 40 Monochrotophos 4.6   5   0    137   Discharged 
20 M 35 Anilphos  4.9   5   0    134   Discharged 
21 M 30 Monochrotophos 2.3   4   4    137   Death 
22 M 32 Phosphomidon 5.2   5   0    138   Discharged 
23 M 25 Chlorpyriphos 2.6   6   4    136   Death 
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24 M 31 Chlorpyriphos 5   7   0    139   Discharged 
25 M 50 Chlorpyriphos 2.8   13   4    137   Discharged 
26 M 30 Monochrotophos 4.8   7   7    138   Death 
27 M 60 Monochrotophos 2.4   2   2    140   Death 
28 M 26 Temephos 5.2   9   3    135   Discharged 
29 M 28 Fenthion  3   7   4    139   Death 
30 M 45 Monochrotophos 5   5   1    137   Discharged 
31 M 45 Chlorpyriphos 5.3   9   2    136   Discharged 
32 M 50 Malathion 2   5   0    138   Discharged 
33 F 35 Diazinon  4.9   5   0    134   Discharged 
34 F 35 Monochrotophos 4.8   5   0    135   Discharged 
35 F 25 Fenthion  4.4   4   0    133   Discharged 
36 M 25 Methyl parathion 4.5   4   0    137   Discharged 
37 M 55 Chlorthiophos 3.1   6   0    133   Discharged 
38 M 42 Chlorpyriphos 2.7   3   3    136   Death 
39 M 51 Chlorpyriphos 4.7   4   0    139   Discharged 
40 M 40 Monochrotophos 2.3   6   6    131   Death 
41 M 28 Chlorpyriphos 2.8   5   0    138   Discharged 
42 M 42 Temephos 4.8   8   3    137   Discharged 
43 F 45 Acephate  5   3   3    136   Death 
44 M 25 Dimethoate 5.2   18   6    140   Discharged 
45 M 56 Chlorpyriphos 3.1   6   0    133   Discharged 
46 F 25 Triazophos 3   5   0    135   Discharged 
47 M 15 Triazophos 4.5   6   0    138   Discharged 
48 M 35 Diazinon  4.8   4   0    136   Discharged 
49 F 22 Monochrotophos 4.7   5   0    135   Discharged 
50 M 75 Chlorpyriphos 4.9   4   4    138   Death 
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